Collateral Lethality in Cancer

Collateral lethality refers to the deletion of genes adjacent to the tumor suppressor genes. These genes though are not involved in cancer progression gets deleted when TSG gets blocked or disabled due to proximity to tumor suppressor genes. These deleted genes act as points of selective vulnerability for developing novel molecular targeted therapeutic strategy. For example in most pancreatic cancer cases, the TSG SMAD4 gets deleted along with ME2 gene which is in close proximity due to collateral lethality. The deletion of ME2 is compensated by the increased expression of its sister gene ME3. Hence therapies involving the inhibition of ME3 results in regulated apoptosis and decreased cell proliferation.

  • Track 1-1 Deletion of adjacent genes
  • Track 2-2 Points of selective vulnerability
  • Track 3-3 Novel strategy
  • Track 4-4 Regulated apoptosis
  • Track 5-5 Decreased Cell proliferation

Related Conference of Oncology & Cancer